Alexander Cherkassky

Little-known Interesting Facts about Liverpool FC

A senior business executive in Massachusetts, Alexander Cherkassky has worked in the fields of life science, diagnostics, and biotechnology industry. His areas of specialization include business analysis and planning, risk mitigation, product management, change management, and performance improvement. Outside of his career, Alexander Cherkassky enjoys the English Premier League, and his favorite team is Liverpool FC.

Liverpool FC is based in Liverpool, England, with a large global following. Below are some interesting facts about Liverpool FC:

Second Club with the Most Titles

Between the years 1889 to 2020, Liverpool came second after Manchester United won 19 titles, closely behind Manchester’s 20 titles. Other clubs, such as Arsenal FC, have 13 titles, Everton FC has nine titles, and Aston Villa has seven titles.

Liverpool wore a different Kit Color

Many people think Liverpool FC has always worn red kits. However, the club originally wore blue and white kits until they were changed in 1896.

15 Players have Scored Goals for 7 Continuous Days

During their time at Liverpool, a total of 15 players managed to score goals consecutively on each of the seven days of the week. Sadio Mane, Divock Origi, and Mohamed Salah were among some of Liverpool’s players who achieved this feat.

Quickest Goal from Joe Cole

Joel Cole’s 27-second goal in favor of Liverpool FC was recorded as the club’s quickest goal that he scored at Anfield in 2010, in a match against Steaua Bucharest.

Standard BioTools Rolls Out Agricultural Genomics Solutions

With a master’s degree in bioinformatics from Northeastern University and Boston University, Alexander Cherkassky is a Massachusetts executive who has led several ventures in the areas of genomics, bioinformatics, and analytical chemistry (mass spectrometry). From 2018 to 2022, Alexander Cherkassky led the mass cytometry and imaging mass cytometry franchise of Standard BioTools, Inc. in San Francisco, California.

Standard BioTools has rolled out multiple technological solutions for agricultural genomics applications ranging from tools that aid pathogen detection to molecular-assisted breeding solutions. Leveraging these technologies can pave the way for sustainable farm operations in the middle of a growing population and rapidly-adjusting climate.

Standard BioTools offers customizable assay designs for diverse species and research goals. Its proprietary technologies are also flexible and can adapt to changing needs. Two notable examples of Standard BioTools’ flagship microfluidics collections are Biomark X and Juno Systems. Both tools facilitate the next-generation sequencing of genetic materials.

Microfluidics Market Projection for 2030

A Wayland, Massachusetts-based clinical product development executive with extensive experience in the healthcare industry, Alexander Cherkassky served as vice president and general manager of Standard BioTools, Inc. Alexander Cherkassky’s efforts at Standard BioTools included the creation of life science tools that can visualize over 30 cellular parameters simultaneously in blood and tissue samples. Standard BioTools rolls out microfluidics solutions to support medical and agricultural research.

According to a market report from Globe Newswire, the global microfluidics market is projected to be worth $106.85 million by 2030. This projection is backed by a CAGR reckoned at 19.5 percent through 2021. One notable market propeller is point-of-care diagnostics, which is growing in relevance and application in the modern world. Point-of-care diagnostics’ salience also points to the advancement of microfluidics tools in the foreseeable future, as multiple companies are engaged in R&D efforts geared toward generating more portable and powerful microfluidics tools.

Microfluidics is the study of systems that analyze minuscule quantities of fluids. Microfluidics systems are applied in genetic material amplification, immunoassays, DNA analysis, cell patterning, and cell manipulation, among other areas. These systems serve invaluable roles in cancer research and therapeutic drug testing.

Liverpool Seal FA Cup Victory against Chelsea at Wembley Stadium

A vice president and franchise head with biotechnology company Fluidigm Inc., Alexander Cherkassky has led his franchise to achieving 28 percent growth since joining in August 2018. He lives in Wayland, Massachusetts. In his free time, Alexander Cherkassky enjoys playing and watching soccer. His favorite team is Liverpool FC.

Liverpool emerged victorious at the FA Cup final on May 14, 2022 at Wembley Stadium after a nerve-wracking penalty shootout against Chelsea FC. The two teams played a superb 90-minute game that ended goalless, prompting an additional 30 minutes of extra time. Despite several chances, however, none of the teams were able to place the ball at the back of the net after a complete 110 minutes of play. The game was settled by a penalty shootout, with Kostas Tsimikas scoring the decisive penalty that handed Liverpool a 6-5 win and their first FA Cup victory since the 2005-2006 season.

Even though they won the final, the long, grueling match did extract a heavy toll on Liverpool, with star striker Mohamed Salah limping off after 33 minutes of play with a groin injury, and center-half Virgil van Dijk not able to play after 90 minutes because of an injured muscle. This has raised concerns over the possibility that the two will not be able to play for the remainder of the 2021-2022 Premier League season. Liverpool is still in contention for the 2021-2022 Premier League Trophy, and has already won two major titles this season, the Carabao Cup and the FA Cup.

New Therapies for Newborns Underused Due to Underdiagnosis

Alexander Cherkassky is a Massachusuets-based vice president and general manager of Fluidigm Inc. Alexander has previously worked at PerkinElmer. while at Perkinelmer, One of the major services that Alexander Cherkassky’s company provided is the screening of newborns for genetic diseases, a process which is constantly being updated with new methods and therapies.

Developing new screening methods for newborns has the potential to improve lives and give millions of children born with genetic illnesses a better chance of receiving treatment and support early in life. However, the lag between developing a new procedure and integrating into mainstream healthcare means that many infants are unable to benefit from them.

A 2021 report in the online journal JAMA Network Open pointed out that one barrier to the use of novel therapies is the mismatch between the efficacy of screening and the respective therapies that are widely available. In short, even though transformative treatments may be available for certain conditions, the existing screening tools do not pick up on the issues in newborns often enough or soon enough for them to be prescribed those treatments. The pipeline of new therapies is seemingly more efficient than the updates to screening procedures that would allow such new therapies to be applied where they are needed most. Screening procedures are slow to adapt, as they require updated technology that is not readily available everywhere.

Fluidigm Announced a Strategic Capital Infusion

A life science professional and entrepreneur with an extensive professional background that includes product development, research, and general administration, Alexander Cherkassky began his two-decade career at Thermo Fisher Scientific as an organic laboratory supervisor. Alexander Cherkassky currently serves as vice president of mass cytometry and spatial tissue imaging franchise, Fluidigm, in California.

On January 24, 2022, the board of the accredited California-based life-science equipment manufacturer Fluidigm Inc. announced the approval of a $250 million capital infusion from Viking Global Investors LP and Casdin Capital LLC. The investors are looking to improve R&D efforts to strengthen and expand the company’s two major platforms – microfluidics and mass cytometry. Casdin and Viking have built solid reputations in the life sciences and biotechnology spheres through strategic capital injections into promising companies in the sectors. Their investment efforts partly center around value creation and an efficient financial structure.

The company expects the investment to close in the first quarter of 2022. The company will likely be renamed Standard BioTools Inc. to reflect its technologies and mission better.

CyTOF® Platform – Cytometric Technologies

A Wayland, Massachusetts-based leader and executive in the health science industry, Alexander Cherkassky received his MS in bioinformatics from Boston University in 2002. Subsequently, he obtained his MBA from the New York Institute of Technology. As the vice president of Fluidigm Inc, focusing on tissue imaging and mass cytometry, Alexander Cherkassky is versed in various cytometric technologies.

The CyTOF® platform is the most advanced cytometric technology in the world. CyTOF®-powered mass cytometry enables simultaneous evaluation of millions of cells using over 50 different markers. CyTOF® has proven efficacy and applicability in various research areas – including immunology, oncology, and epidemiology.

With the CyTOF® platform, researchers can sort samples through barcoding and work with cells in solid and liquid samples. The data generated from each analysis can be recorded in standard Helios or CyTOF® XT data files. These files are compatible with multiple software, including Maxpar Pathsetter and FCS Express.

A Look at the AACC’s Advocacy Priorities

71st American Association for Clinical Chemistry (AACC) Annual Scientific Meeting 2019 | HealthManagement.org

Alexander Cherkassky is an experienced scientist who worked as platform director at Thermo Fisher Scientific in Waltham, Massachusetts, before joining Fluidigm as senior director in 2018. At Fluidigm, he’s responsible for the development of life science tools to visualize more than 30 cellular parameters at single-cell resolution. Complementing his experience, Alexander Cherkassky holds membership with the American Association of Clinical Chemistry (AACC).

A global organization promoting the health care application of clinical laboratory science, the AACC provides industry leadership in education and advocacy. In terms of advocacy, the organization has sought to enact positive change in the following four areas: children’s health, laboratory regulations, patient access to quality testing, and reimbursement and the changing health care environment.

The AACC is particularly engaged in efforts to improve newborn screening and the interpretation of test results through the development of more efficient pediatric reference intervals. In regard to laboratory regulations, the organization supports public policies with the intent to improve the effectiveness and safety of laboratory-developed tests.

The organization also supports widespread access to quality tests, in addition to efforts to improve uniformity across results. It has been active in ensuring patients have access to COVID-19 tests since the beginning of the pandemic. Finally, the AACC is advocating for increases to the Clinical Laboratory Fee Schedule (CLFS). CLFS rates were recently decreased due to troubles with the roll-out of the Protecting Access to Medicare Act.

The Three Most Expensive Transfers in Liverpool FC History

American football football stock pictures, royalty-free photos & images

A member of the International Society of Advancements in Cytometry, Alexander Cherkassky leverages two decades of clinical research and development experience to develop life science tools for Fluidigm, Inc. He has been with the company since 2018 and previously worked as platform director at Thermo Fisher Scientific in Waltham, Massachusetts. Alexander Cherkassky enjoys watching the English Premiership in his free time and counts Liverpool FC as his favorite team.

Every year, teams in the Premiership spend millions of pounds on international transfers. Here is a look at the three most expensive transfers in Liverpool FC history.

1. Virgil van Dijk (£76.2m) – Liverpool purchased center-back van Dijk for £76.2m from Southampton in 2018. While the team spent more on van Dijk than it has on any player in club history, the move paid off on the field. Liverpool reached the Champions League final in van Dijk’s first year with the club and won it the following year. Moreover, van Dijk was runner-up for the Ballon d’Or in 2019.

2. Alisson (£56.3m) – Seeking to address its goalkeeper woes, Liverpool signed Alisson for £56.3m from Roma in 2018. Alisson recorded 28 clean sheets across all competitions during his first year with the team and played an integral role in its Premier League championship in 2020.

3. Naby Keita (£54m) – Signed during the same transfer window as Alisson, Liverpool purchased Keita for £54m from RB Leipzig. The move hasn’t paid off as well as the other two, as the midfielder has been plagued by injuries and has yet to receive the trust of manager Jürgen Klopp.

Fluidigm Partners with the Karolinska Institutet to Advance Treatments

With extensive experience in the healthcare industry, Alexander Cherkassky began his career as ab organic laboratory supervisor at Thermo Fisher Scientific in Massachusetts. Here, he was in charge of scheduling personnel and workflow, as well as overseeing sample analysis and quality control in accordance with US EPA regulations. Since 2018, Alexander Cherkassky has served as the senior director of the national mass cytometry and spatial tissue imaging franchise of San Francisco’s Fluidigm.

On Tuesday, September 28, Fluidigm Corporation, an advanced biotechnology tools supplier with a mission to enhance the quality of living via complete health insight, announced a partnership agreement with the Karolinska Institutet for research and product development using CyTOF® XT. The fourth-generation CyTOF XT platform is based on Fluidigm’s groundbreaking CyTOF technology. The partnership will focus on CyTOF-based research in the Institute’s Women’s and Children’s Health Department.

CyTOF XT™ was launched to make deep cell profiling studies easier for researchers, standardize sample analysis with repeatable processes and automation, and also speed up the development of innovative therapies. Translational and clinical researchers in the pharmaceutical and biotechnology industries, as well as contract research firms that service them, can all benefit from CyTOF XT.

Fluidigm President and CEO Chris Linthwaite stated, “Collaborating with one of the world’s most prestigious medical universities is an honor for Fluidigm, and we are excited to partner with Karolinska Institutet.” The Karolinska Institutet is one of the world’s leading medical institutions and Sweden’s biggest single academic medical research facility. It is situated in Stockholm.